Clinical efficacy of ertapenem vs. other carbapenems for the treatment of extended-spectrum-β-lactamase-producing Enterobacterales infection: A systematic review and meta-analysis

Abstract

Both ertapenem and other carbapenems, including imipenem, meropenem, and doripenem, are recommended in the treatment of extended-spectrum-β-lactamase (ESBL)-producing Enterobacterales infection. However, whether ertapenem is as effective as other carbapenems for ESBL-producing Enterobacterales remains unclear. Therefore, this meta-analysis was conducted to compare the clinical efficacy of ertapenem versus other carbapenems in the treatment of ESBL-producing Enterobacterales infection. PubMed, Web of Science, and Cochrane Library were searched from their inception to November 29, 2022. Only studies comparing ertapenem and other carbapenems in the treatment of patients with ESBL-producing Enterobacterales infections were included. A total of 6 studies meeting the selection criteria were identified. Overall, ertapenem was associated with a significantly lower 30-day mortality when compared with other carbapenems (10.7% [46/431] vs 17.7% [104/586]; risk ratio [RR], 0.61; 95% CI: 0.40-0.91). The ertapenem group exhibited a significantly shorter length of hospital stay than the other carbapenems groups (mean differences, -6.02 days; 95% CI, -9.39 to -2.64). No significant differences were noted between the ertapenem and other carbapenems groups in terms of the rates of clinical cure or improvement (RR, 1.11; 95% CI: 0.97-1.25) and microbiological eradication (RR, 1.01; 95% CI: 0.97-1.06). Ertapenem could be as effective as other carbapenems in the treatment of patients with ESBL-producing Enterobacterales infections.